243 related articles for article (PubMed ID: 36872948)
1. The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis.
Tang Y; Shen G; Xin Y; Li Z; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
Ther Adv Med Oncol; 2023; 15():17588359231156669. PubMed ID: 36872948
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis.
Liu M; Xiang Q; Dai F; Yuan Y; Wu Z; Xiang T
Clin Breast Cancer; 2024 May; ():. PubMed ID: 38821742
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.
Wei T; Wang D; Gao S; Wang X; Yue J; Kang Y; Ju J; Yang Z; Shuai Y; Yuan P
Front Oncol; 2023; 13():1100332. PubMed ID: 36816954
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
Xia LY; Cao XC; Yu Y
World J Surg Oncol; 2024 Apr; 22(1):106. PubMed ID: 38643188
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E
ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
9. Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
Zhang S; Liu Y; Liu X; Liu Y; Zhang J
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831499
[TBL] [Abstract][Full Text] [Related]
10. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract][Full Text] [Related]
11. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis.
Petrelli F; Rea C; Parati MC; Borgonovo K; Ghilardi M; Dottorini L; Luciani A; Ghidini M; Ruatta F; Garrone O; Tomasello G
Anticancer Res; 2023 Oct; 43(10):4303-4313. PubMed ID: 37772569
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
14. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
15. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
Lohmann AE; Soldera SV; Pimentel I; Ribnikar D; Ennis M; Amir E; Goodwin PJ
J Natl Cancer Inst; 2021 Nov; 113(11):1465-1475. PubMed ID: 33620467
[TBL] [Abstract][Full Text] [Related]
16. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
17. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
18. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients.
Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K
Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780
[TBL] [Abstract][Full Text] [Related]
19. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
20. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
